Scopia Capital Management LP cut its holdings in shares of Retrophin Inc (NASDAQ:RTRX) by 7.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,884,691 shares of the biopharmaceutical company’s stock after selling 330,281 shares during the period. Retrophin makes up about 3.5% of Scopia Capital Management LP’s portfolio, making the stock its 12th largest holding. Scopia Capital Management LP owned 9.04% of Retrophin worth $78,043,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Retrophin by 3.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,192,002 shares of the biopharmaceutical company’s stock worth $44,036,000 after buying an additional 73,736 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Retrophin by 3.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,944,288 shares of the biopharmaceutical company’s stock worth $43,999,000 after purchasing an additional 73,284 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Retrophin by 6.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,154,859 shares of the biopharmaceutical company’s stock worth $26,134,000 after purchasing an additional 67,834 shares during the last quarter. Rock Springs Capital Management LP raised its position in shares of Retrophin by 14.5% during the 2nd quarter. Rock Springs Capital Management LP now owns 950,000 shares of the biopharmaceutical company’s stock valued at $19,086,000 after buying an additional 120,000 shares during the period. Finally, Handelsbanken Fonder AB raised its position in shares of Retrophin by 32.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 612,856 shares of the biopharmaceutical company’s stock valued at $12,312,000 after buying an additional 150,000 shares during the period.
NASDAQ RTRX traded up $0.06 on Friday, reaching $12.44. The stock had a trading volume of 24,808 shares, compared to its average volume of 1,155,158. The firm has a market capitalization of $515.88 million, a price-to-earnings ratio of -4.90 and a beta of 0.92. The company has a quick ratio of 4.99, a current ratio of 5.05 and a debt-to-equity ratio of 0.72. Retrophin Inc has a 12-month low of $11.39 and a 12-month high of $29.70. The stock has a fifty day moving average price of $14.98 and a two-hundred day moving average price of $19.12.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.27). The business had revenue of $44.71 million during the quarter, compared to analyst estimates of $43.01 million. Retrophin had a negative return on equity of 47.21% and a negative net margin of 83.94%. The business’s revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.25) EPS. Sell-side analysts forecast that Retrophin Inc will post -4.03 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. BMO Capital Markets reduced their price target on shares of Retrophin from $38.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, August 23rd. BidaskClub lowered shares of Retrophin from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 27th. Canaccord Genuity reduced their price target on shares of Retrophin from $38.00 to $23.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd. Jefferies Financial Group set a $33.00 price target on shares of Retrophin and gave the company a “buy” rating in a research report on Friday, August 23rd. Finally, Nomura reduced their price target on shares of Retrophin from $57.00 to $33.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $29.71.
In other Retrophin news, insider Noah L. Rosenberg sold 2,500 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $19.95, for a total value of $49,875.00. Following the completion of the transaction, the insider now owns 14,750 shares in the company, valued at $294,262.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.32% of the company’s stock.
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Article: How to invest using market indexes